AI¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ·Î Á¤º¸ ¼Ö·ç¼Ç °³¹ß °¡¼ÓÈ ¹× Çõ½ÅÀû ¼ºÀå ÃËÁø
ÀÌ Frost & Sullivan ºÐ¼® º¸°í¼´Â ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì(NGS) »ê¾÷À» Á¶»çÇÏ¿© ´Ù¾çÇÑ À¯ÇüÀÇ Á¦Ç°, ¿öÅ©ÇÃ·Î¿ì ¹× ÀÓ»ó ¸ñÀûÀÇ ÀÀ¿ë ºÐ¾ß¸¦ Æ÷°ýÇÕ´Ï´Ù. NGS ½ÃÀåÀº 2024-2030³â µ¿¾È ¼ºñ½º ¹× ÀÎÆ÷¸Åƽ½º ºÎ¹®ÀÌ ÁÖ¿ä ¿øµ¿·ÂÀ¸·Î ÀÛ¿ëÇØ ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, NGS ½ÃÀå¿¡´Â Á¦¾à, »ý¸í°øÇÐ, Áø´Ü µî ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®ÀÇ ÀÓ»óÀû ¿ëµµ¸¦ À§ÇÑ ´Ù¾çÇÑ À¯ÇüÀÇ Á¦Ç° ¹× ¿öÅ©Ç÷ο찡 Æ÷ÇԵ˴ϴÙ. ¶óÀ̺귯¸® Áغñ, ½ÃÄö½Ì, µ¥ÀÌÅÍ ºÐ¼® ¹× ÇØ¼®À» Æ÷ÇÔÇÑ ¿£µå-Åõ-¿£µå ¿öÅ©Ç÷ο츦 Æ÷ÇÔÇϸç, Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, Áø´Ü µî ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®ÀÇ ÀÓ»ó ÀÀ¿ëÀ» À§ÇØ Æ¯º°È÷ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌµé ºÐ¾ß¿¡¼ NGS ±â¼úÀº ÁÖ·Î Áúº´ Áø´Ü ¹× ¸ð´ÏÅ͸µ, µ¿¹ÝÁø´Ü, ÀÓ»ó½ÃÇè, ȯÀÚ °èÃþÈ µî¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC), ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä« ¹× ³²¾Æ½Ã¾Æ(MEASA) Áö¿ªÀÇ »ç·Ê ¿¬±¸¸¦ ÅëÇØ ÀÓ»ó ÇöÀå¿¡¼ NGS ±â¼ú »ç¿ëÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ» Æò°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå ¼öÀͰú ¿¹Ãø»Ó¸¸ ¾Æ´Ï¶ó »ê¾÷ ºÎ¹®, ±ÔÁ¦ ȯ°æ, »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨À» Æò°¡ÇÏ¿© ¾÷°è°¡ Á¦½ÃÇÏ´Â ÇÙ½É ¼ºÀå ±âȸµµ ÆÄ¾ÇÇÕ´Ï´Ù.
¸ñÂ÷
»ýŰè
¼ºÀå ȯ°æ : ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì º¯Çõ
- ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö´Â°¡?
- The Strategic Imperative 8(TM)
- ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì ¾÷°èÀÇ »óÀ§ 3°³ Àü·«Àû °úÁ¦ÀÇ ¿µÇâ
ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì »ýŰè
ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½ÌÀÇ ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ÁöÇ¥
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ¿¹Ãø¿¡ °üÇÑ ÀλçÀÌÆ®
- ¸ÅÃâ ¿¹Ãø
- Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
- ¿öÅ©Ç÷ο캰 ¸ÅÃâ ¿¹Ãø
- ¿ëµµº° ¸ÅÃâ ¿¹Ãø
- Áö¿ªº° ¸ÅÃâ ¿¹Ãø
- ¸ÅÃâ ¿¹Ãø ºÐ¼®
- °¡°Ý µ¿Çâ°ú ¿¹Ãø ºÐ¼®
- ¸ÅÃâ Á¡À¯À²
- ¸ÅÃâ Á¡À¯À² ºÐ¼®
- °æÀï»ç
- ±â¾÷ ¾ÖÇø®ÄÉÀ̼ǿë ÀÎÆ÷¸Åƽ½º ¼Ö·ç¼Ç
¼ºÀå ÃËÁø¿äÀÎ : ±â±â
- ¼ºÀå ÁöÇ¥
- ¸ÅÃâ ¿¹Ãø
- Áö¿ªº° ¸ÅÃâ ¿¹Ãø
- ¿¹Ãø ºÐ¼®
¼ºÀå ÃËÁø¿äÀÎ : ¿öÅ©ÇÃ·Î¿ì ¼Ö·ç¼Ç
- ¼ºÀå ÁöÇ¥
- ¸ÅÃâ ¿¹Ãø
- Áö¿ªº° ¸ÅÃâ ¿¹Ãø
- ¿¹Ãø ºÐ¼®
¼ºÀå ÃËÁø¿äÀÎ : ¼ºñ½º
- ¼ºÀå ÁöÇ¥
- ¸ÅÃâ ¿¹Ãø
- Áö¿ªº° ¸ÅÃâ ¿¹Ãø
- ¿¹Ãø ºÐ¼®
¼ºÀå ÃËÁø¿äÀÎ : ÀÎÆ÷¸Åƽ½º
- ¼ºÀå ÁöÇ¥
- ¸ÅÃâ ¿¹Ãø
- Áö¿ªº° ¸ÅÃâ ¿¹Ãø
- ¿¹Ãø ºÐ¼®
ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì ºÐ¾ß ¼ºÀå ±âȸ ¿µ¿ª ºÐ¼®
- ¼ºÀå ±âȸ 1 : ¸ÂÃãÇü ÀǷḦ À§ÇÑ ¸ÖƼ¿À¹Í½º µ¥ÀÌÅÍÀÇ ÅëÇÕ
- ¼ºÀå ±âȸ 2 : ¾ÏÀÇ ÃÖ¼Ò ÀÜÁ¸ º´º¯ °ËÃâ°ú Ä¡·á
- ¼ºÀå ±âȸ 3 : ÀÓ»ó ¿¬±¸ÀÇ ´ÜÀϼ¼Æ÷ ¹× °ø°£ ¿À¹Í½º È®´ë
- ¼ºÀå ±âȸ 4 : ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× Áßµ¿¡¤¾ÆÇÁ¸®Ä«¡¤³²¾Æ½Ã¾ÆÀÇ À¯ÀüüÇп¡ ´ëÇÑ ´ëó¿Í ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ¹ßÀü
ºÎ·Ï°ú ´ÙÀ½ ½ºÅÜ
- ¼ºÀå ±âȸÀÇ ÀÌÁ¡°ú ÀÓÆÑÆ®
- ´ÙÀ½ ½ºÅÜ
- º°Áö ¸®½ºÆ®
- ¸éÃ¥»çÇ×
ksm
Continued Investment in AI is Driving Transformational Growth by Accelerating Information Solutions Development
This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. The NGS market encompasses end-to-end workflows, including library preparation, sequencing, and data analysis and interpretation, specifically designed for clinical applications across key end-user segments: pharmaceutical and biotechnology, and diagnostics. Within these sectors, NGS technologies are primarily employed to diagnose and monitor diseases, as well as for companion diagnostics, clinical trials, and patient stratification.
This analysis assesses the factors driving and restraining the growth of the use of NGS technology in clinical settings and offers case studies from North America, Europe, Asia-Pacific (APAC), Latin America, and the Middle East, Africa, and South Asia (MEASA). It also identifies the core growth opportunities that the industry presents by evaluating industry segments, the regulatory environment, and emerging business models, as well as market revenue and forecasts.
Table of Contents
Ecosystem
- Scope of Analysis
- Segmentation
Growth Environment: Transformation in Clinical Next-generation Sequencing
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- The Impact of the Top 3 Strategic Imperatives on the Clinical Next-generation Sequencing Industry
Ecosystem in Clinical Next-generation Sequencing
- Competitive Environment
- Key Competitors
Growth Generator in Clinical Next-generation Sequencing
- Growth Metrics
- Growth Drivers
- Growth Restraints
- Forecast Considerations
- Revenue Forecast
- Revenue Forecast by Product
- Revenue Forecast by Workflow
- Revenue Forecast by Application
- Revenue Forecast by Region
- Revenue Forecast Analysis
- Pricing Trends and Forecast Analysis
- Revenue Share
- Revenue Share Analysis
- Competitive Players
- Company Informatics Solutions for Applications
Growth GeneratorInstruments
- Growth Metrics
- Revenue Forecast
- Revenue Forecast by Region
- Forecast Analysis
Growth GeneratorWorkflow Solutions
- Growth Metrics
- Revenue Forecast
- Revenue Forecast by Region
- Forecast Analysis
Growth GeneratorServices
- Growth Metrics
- Revenue Forecast
- Revenue Forecast by Region
- Forecast Analysis
Growth GeneratorInformatics
- Growth Metrics
- Revenue Forecast
- Revenue Forecast by Region
- Forecast Analysis
Growth Opportunity Universe Analysis of the Clinical Next-generation Sequencing Sector
- Growth Opportunity 1: Integration of Multi-omics Data for Personalized Medicine
- Growth Opportunity 2: Minimal Residual Disease Detection and Treatment in Cancer
- Growth Opportunity 3: Expansion of Single-cell and Spatial Omics in Clinical Research
- Growth Opportunity 4: Genomics Initiatives and Bioinformatics Development in APAC and MEASA
Appendix & Next Steps
- Benefits and Impacts of Growth Opportunities
- Next Steps
- List of Exhibits
- Legal Disclaimer